AustralieFrV1, Main, Exploration, bibRecord, 008405

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Identifieur interne : 008405 ( Main/Exploration ); précédent : 008404; suivant : 008406

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Auteurs : Jane F. Apperley [Royaume-Uni, États-Unis, Corée du Sud, France, Italie, Argentine, Allemagne, Suisse, Brésil, Canada, Autriche, Australie] ; Jorge E. Cortes ; Dong-Wook Kim ; Lydia Roy ; Gail J. Roboz ; Gianantonio Rosti ; Eduardo O. Bullorsky ; Elisabetta Abruzzese ; Andreas Hochhaus ; Dominik Heim ; Carmino A. De Souza ; Richard A. Larson ; Jeffrey H. Lipton ; H. Jean Khoury ; Hyeoung-Joon Kim ; Christian Sillaber ; Timothy P. Hughes ; Philipp Erben ; Jan Van Tornout ; Richard M. Stone

Source :

Journal of clinical oncology [ 0732-183X ] ; 2009.

RBID : Pascal:09-0326540

Descripteurs français

Pascal (Inist)
- Dasatinib, Anticancéreux, Traitement, Imatinib, Leucémie myéloïde chronique, Protein-tyrosine kinase, Inhibiteur enzyme, Essai clinique, Cancérologie.

English descriptors

KwdEn :
- Antineoplastic agent, Cancerology, Chronic myelogenous leukemia, Clinical trial, Dasatinib, Enzyme inhibitor, Imatinib, Protein-tyrosine kinase, Treatment.

Abstract

Purpose Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy in patients with CML-AP who have experienced treatment failure with imatinib. We now report follow-up data from the full patient cohort of 174 patients enrolled onto a phase II trial to provide a more complete assessment of the efficacy and safety of dasatinib in this population. Patients and Methods Patients with imatinib-resistant (n = 161) or -intolerant (n = 13) CML-AP received dasatinib 70 mg orally twice daily. Results At a median follow-up of 14.1 months (treatment duration, 0.1 to 21.7 months), major and complete hematologic responses were attained by 64% and 45% of patients, respectively, and major and complete cytogenetic responses were achieved in 39% and 32% of patients, respectively. Responses were achieved irrespective of imatinib status (resistant or intolerant), prior stem-cell transplantation, or the presence of prior BCR-ABL mutation. The 12-month progression-free survival and overall survival rates were 66% and 82%, respectively. Dasatinib was generally well tolerated; the most frequent nonhematologic severe treatment-related adverse event was diarrhea (52%; grade 3 to 4, 8%). Cytopenias were common, including grade 3 to 4 neutropenia (76%) and thrombocytopenia (82%). Pleural effusion occurred in 27% of patients (grade 3 to 4, 5%). Conclusion Dasatinib is effective in patients with CML-AP after imatinib treatment failure.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979080

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial</title>
<author><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>From the Hammersmith Hospital, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Texas M. D. Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Texas M. D. Anderson Cancer Center</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>St Mary's Hospital, the Catholic University of Korea</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Chonnam National University</s1>
<s2>Hwasun-gun, Jeollanam-do</s2>
<s3>KOR</s3>
</inist:fA14>
<country>Corée du Sud</country>
<wicri:noRegion>Chonnam National University</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Clinical Research Center, Centre Hospitalier Universitaire de Poitiers</s1>
<s2>Poitiers</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Weill Medical College of Cornell University, New York Presbyterian Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>S Orsola-Malpighi University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>S Orsola-Malpighi University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Ospedale S. Eugenio</s1>
<s2>Rome</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>British Hospital of Buenos Aires</s1>
<s3>ARG</s3>
</inist:fA14>
<country>Argentine</country>
<wicri:noRegion>British Hospital of Buenos Aires</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Medizinische Fakultät Mannheim, Universität Heidelberg</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>University Hospital</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="12"><s1>Universidade Estadual De Campinas</s1>
<s2>Campinas</s2>
<s3>BRA</s3>
</inist:fA14>
<country>Brésil</country>
<placeName><settlement type="city">Campinas</settlement>
<region type="state">État de São Paulo</region>
</placeName>
<orgName type="university">Université d'État de Campinas</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>University of Chicago</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Chicago</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Emory University School of Medicine</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="16"><s1>Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>University of Adelaide</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>University of Adelaide</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Bristol-Myers Squibb</s1>
<s2>Wallingford, CT</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Bristol-Myers Squibb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="19"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Dana-Farber Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
</author>
<author><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
</author>
<author><name sortKey="Roy, Lydia" sort="Roy, Lydia" uniqKey="Roy L" first="Lydia" last="Roy">Lydia Roy</name>
</author>
<author><name sortKey="Roboz, Gail J" sort="Roboz, Gail J" uniqKey="Roboz G" first="Gail J." last="Roboz">Gail J. Roboz</name>
</author>
<author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name>
</author>
<author><name sortKey="Bullorsky, Eduardo O" sort="Bullorsky, Eduardo O" uniqKey="Bullorsky E" first="Eduardo O." last="Bullorsky">Eduardo O. Bullorsky</name>
</author>
<author><name sortKey="Abruzzese, Elisabetta" sort="Abruzzese, Elisabetta" uniqKey="Abruzzese E" first="Elisabetta" last="Abruzzese">Elisabetta Abruzzese</name>
</author>
<author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
</author>
<author><name sortKey="Heim, Dominik" sort="Heim, Dominik" uniqKey="Heim D" first="Dominik" last="Heim">Dominik Heim</name>
</author>
<author><name sortKey="De Souza, Carmino A" sort="De Souza, Carmino A" uniqKey="De Souza C" first="Carmino A." last="De Souza">Carmino A. De Souza</name>
</author>
<author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name>
</author>
<author><name sortKey="Lipton, Jeffrey H" sort="Lipton, Jeffrey H" uniqKey="Lipton J" first="Jeffrey H." last="Lipton">Jeffrey H. Lipton</name>
</author>
<author><name sortKey="Khoury, H Jean" sort="Khoury, H Jean" uniqKey="Khoury H" first="H. Jean" last="Khoury">H. Jean Khoury</name>
</author>
<author><name sortKey="Kim, Hyeoung Joon" sort="Kim, Hyeoung Joon" uniqKey="Kim H" first="Hyeoung-Joon" last="Kim">Hyeoung-Joon Kim</name>
</author>
<author><name sortKey="Sillaber, Christian" sort="Sillaber, Christian" uniqKey="Sillaber C" first="Christian" last="Sillaber">Christian Sillaber</name>
</author>
<author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name>
</author>
<author><name sortKey="Erben, Philipp" sort="Erben, Philipp" uniqKey="Erben P" first="Philipp" last="Erben">Philipp Erben</name>
</author>
<author><name sortKey="Van Tornout, Jan" sort="Van Tornout, Jan" uniqKey="Van Tornout J" first="Jan" last="Van Tornout">Jan Van Tornout</name>
</author>
<author><name sortKey="Stone, Richard M" sort="Stone, Richard M" uniqKey="Stone R" first="Richard M." last="Stone">Richard M. Stone</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">09-0326540</idno>
<date when="2009">2009</date>
<idno type="stanalyst">PASCAL 09-0326540 INIST</idno>
<idno type="RBID">Pascal:09-0326540</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002C84</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003336</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C20</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002C20</idno>
<idno type="wicri:doubleKey">0732-183X:2009:Apperley J:dasatinib:in:the</idno>
<idno type="wicri:Area/Main/Merge">008B89</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979080</idno>
<idno type="RBID">PMC:4979080</idno>
<idno type="wicri:Area/Pmc/Corpus">001942</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001942</idno>
<idno type="wicri:Area/Pmc/Curation">001801</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001801</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002833</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002833</idno>
<idno type="wicri:Area/Ncbi/Merge">000595</idno>
<idno type="wicri:Area/Ncbi/Curation">000595</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000595</idno>
<idno type="wicri:doubleKey">0732-183X:2009:Apperley J:dasatinib:in:the</idno>
<idno type="wicri:Area/Main/Merge">008313</idno>
<idno type="wicri:Area/Main/Curation">008405</idno>
<idno type="wicri:Area/Main/Exploration">008405</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial</title>
<author><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>From the Hammersmith Hospital, Imperial College</s1>
<s2>London</s2>
<s3>GBR</s3>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>University of Texas M. D. Anderson Cancer Center</s1>
<s2>Houston, TX</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Texas M. D. Anderson Cancer Center</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>St Mary's Hospital, the Catholic University of Korea</s1>
<s2>Seoul</s2>
<s3>KOR</s3>
</inist:fA14>
<country>Corée du Sud</country>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Chonnam National University</s1>
<s2>Hwasun-gun, Jeollanam-do</s2>
<s3>KOR</s3>
</inist:fA14>
<country>Corée du Sud</country>
<wicri:noRegion>Chonnam National University</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="05"><s1>Clinical Research Center, Centre Hospitalier Universitaire de Poitiers</s1>
<s2>Poitiers</s2>
<s3>FRA</s3>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Nouvelle-Aquitaine</region>
<region type="old region">Poitou-Charentes</region>
<settlement type="city">Poitiers</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Weill Medical College of Cornell University, New York Presbyterian Hospital</s1>
<s2>New York, NY</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>New York, NY</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>S Orsola-Malpighi University Hospital</s1>
<s2>Bologna</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<wicri:noRegion>S Orsola-Malpighi University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="08"><s1>Ospedale S. Eugenio</s1>
<s2>Rome</s2>
<s3>ITA</s3>
</inist:fA14>
<country>Italie</country>
<placeName><settlement type="city">Rome</settlement>
<region nuts="2">Latium</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>British Hospital of Buenos Aires</s1>
<s3>ARG</s3>
</inist:fA14>
<country>Argentine</country>
<wicri:noRegion>British Hospital of Buenos Aires</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="10"><s1>Medizinische Fakultät Mannheim, Universität Heidelberg</s1>
<s2>Mannheim</s2>
<s3>DEU</s3>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Mannheim</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>University Hospital</s1>
<s2>Basel</s2>
<s3>CHE</s3>
</inist:fA14>
<country>Suisse</country>
<wicri:noRegion>University Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="4"><inist:fA14 i1="12"><s1>Universidade Estadual De Campinas</s1>
<s2>Campinas</s2>
<s3>BRA</s3>
</inist:fA14>
<country>Brésil</country>
<placeName><settlement type="city">Campinas</settlement>
<region type="state">État de São Paulo</region>
</placeName>
<orgName type="university">Université d'État de Campinas</orgName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="13"><s1>University of Chicago</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>University of Chicago</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="14"><s1>Princess Margaret Hospital</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Princess Margaret Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="15"><s1>Emory University School of Medicine</s1>
<s2>Atlanta, GA</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Emory University School of Medicine</wicri:noRegion>
</affiliation>
<affiliation wicri:level="3"><inist:fA14 i1="16"><s1>Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
</inist:fA14>
<country>Autriche</country>
<placeName><settlement type="city">Vienne (Autriche)</settlement>
<region nuts="2" type="province">Vienne (Autriche)</region>
</placeName>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="17"><s1>University of Adelaide</s1>
<s2>Adelaide</s2>
<s3>AUS</s3>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>University of Adelaide</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="18"><s1>Bristol-Myers Squibb</s1>
<s2>Wallingford, CT</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Bristol-Myers Squibb</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="19"><s1>Dana-Farber Cancer Institute</s1>
<s2>Boston, MA</s2>
<s3>USA</s3>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Dana-Farber Cancer Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
</author>
<author><name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
</author>
<author><name sortKey="Roy, Lydia" sort="Roy, Lydia" uniqKey="Roy L" first="Lydia" last="Roy">Lydia Roy</name>
</author>
<author><name sortKey="Roboz, Gail J" sort="Roboz, Gail J" uniqKey="Roboz G" first="Gail J." last="Roboz">Gail J. Roboz</name>
</author>
<author><name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name>
</author>
<author><name sortKey="Bullorsky, Eduardo O" sort="Bullorsky, Eduardo O" uniqKey="Bullorsky E" first="Eduardo O." last="Bullorsky">Eduardo O. Bullorsky</name>
</author>
<author><name sortKey="Abruzzese, Elisabetta" sort="Abruzzese, Elisabetta" uniqKey="Abruzzese E" first="Elisabetta" last="Abruzzese">Elisabetta Abruzzese</name>
</author>
<author><name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
</author>
<author><name sortKey="Heim, Dominik" sort="Heim, Dominik" uniqKey="Heim D" first="Dominik" last="Heim">Dominik Heim</name>
</author>
<author><name sortKey="De Souza, Carmino A" sort="De Souza, Carmino A" uniqKey="De Souza C" first="Carmino A." last="De Souza">Carmino A. De Souza</name>
</author>
<author><name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name>
</author>
<author><name sortKey="Lipton, Jeffrey H" sort="Lipton, Jeffrey H" uniqKey="Lipton J" first="Jeffrey H." last="Lipton">Jeffrey H. Lipton</name>
</author>
<author><name sortKey="Khoury, H Jean" sort="Khoury, H Jean" uniqKey="Khoury H" first="H. Jean" last="Khoury">H. Jean Khoury</name>
</author>
<author><name sortKey="Kim, Hyeoung Joon" sort="Kim, Hyeoung Joon" uniqKey="Kim H" first="Hyeoung-Joon" last="Kim">Hyeoung-Joon Kim</name>
</author>
<author><name sortKey="Sillaber, Christian" sort="Sillaber, Christian" uniqKey="Sillaber C" first="Christian" last="Sillaber">Christian Sillaber</name>
</author>
<author><name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name>
</author>
<author><name sortKey="Erben, Philipp" sort="Erben, Philipp" uniqKey="Erben P" first="Philipp" last="Erben">Philipp Erben</name>
</author>
<author><name sortKey="Van Tornout, Jan" sort="Van Tornout, Jan" uniqKey="Van Tornout J" first="Jan" last="Van Tornout">Jan Van Tornout</name>
</author>
<author><name sortKey="Stone, Richard M" sort="Stone, Richard M" uniqKey="Stone R" first="Richard M." last="Stone">Richard M. Stone</name>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2009">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Chronic myelogenous leukemia</term>
<term>Clinical trial</term>
<term>Dasatinib</term>
<term>Enzyme inhibitor</term>
<term>Imatinib</term>
<term>Protein-tyrosine kinase</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dasatinib</term>
<term>Anticancéreux</term>
<term>Traitement</term>
<term>Imatinib</term>
<term>Leucémie myéloïde chronique</term>
<term>Protein-tyrosine kinase</term>
<term>Inhibiteur enzyme</term>
<term>Essai clinique</term>
<term>Cancérologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose Patients with chronic myelogenous leukemia in accelerated phase (CML-AP) that is resistant or intolerant to imatinib have limited therapeutic options. Dasatinib, a potent inhibitor of BCR-ABL and SRC-family kinases, has efficacy in patients with CML-AP who have experienced treatment failure with imatinib. We now report follow-up data from the full patient cohort of 174 patients enrolled onto a phase II trial to provide a more complete assessment of the efficacy and safety of dasatinib in this population. Patients and Methods Patients with imatinib-resistant (n = 161) or -intolerant (n = 13) CML-AP received dasatinib 70 mg orally twice daily. Results At a median follow-up of 14.1 months (treatment duration, 0.1 to 21.7 months), major and complete hematologic responses were attained by 64% and 45% of patients, respectively, and major and complete cytogenetic responses were achieved in 39% and 32% of patients, respectively. Responses were achieved irrespective of imatinib status (resistant or intolerant), prior stem-cell transplantation, or the presence of prior BCR-ABL mutation. The 12-month progression-free survival and overall survival rates were 66% and 82%, respectively. Dasatinib was generally well tolerated; the most frequent nonhematologic severe treatment-related adverse event was diarrhea (52%; grade 3 to 4, 8%). Cytopenias were common, including grade 3 to 4 neutropenia (76%) and thrombocytopenia (82%). Pleural effusion occurred in 27% of patients (grade 3 to 4, 5%). Conclusion Dasatinib is effective in patients with CML-AP after imatinib treatment failure.</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Argentine</li>
<li>Australie</li>
<li>Autriche</li>
<li>Brésil</li>
<li>Canada</li>
<li>Corée du Sud</li>
<li>France</li>
<li>Italie</li>
<li>Royaume-Uni</li>
<li>Suisse</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Bade-Wurtemberg</li>
<li>District de Karlsruhe</li>
<li>Grand Londres</li>
<li>Latium</li>
<li>Nouvelle-Aquitaine</li>
<li>Poitou-Charentes</li>
<li>Région capitale de Séoul</li>
<li>Vienne (Autriche)</li>
<li>État de São Paulo</li>
</region>
<settlement><li>Campinas</li>
<li>Londres</li>
<li>Mannheim</li>
<li>Poitiers</li>
<li>Rome</li>
<li>Séoul</li>
<li>Vienne (Autriche)</li>
</settlement>
<orgName><li>Université d'État de Campinas</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Abruzzese, Elisabetta" sort="Abruzzese, Elisabetta" uniqKey="Abruzzese E" first="Elisabetta" last="Abruzzese">Elisabetta Abruzzese</name>
<name sortKey="Bullorsky, Eduardo O" sort="Bullorsky, Eduardo O" uniqKey="Bullorsky E" first="Eduardo O." last="Bullorsky">Eduardo O. Bullorsky</name>
<name sortKey="Cortes, Jorge E" sort="Cortes, Jorge E" uniqKey="Cortes J" first="Jorge E." last="Cortes">Jorge E. Cortes</name>
<name sortKey="De Souza, Carmino A" sort="De Souza, Carmino A" uniqKey="De Souza C" first="Carmino A." last="De Souza">Carmino A. De Souza</name>
<name sortKey="Erben, Philipp" sort="Erben, Philipp" uniqKey="Erben P" first="Philipp" last="Erben">Philipp Erben</name>
<name sortKey="Heim, Dominik" sort="Heim, Dominik" uniqKey="Heim D" first="Dominik" last="Heim">Dominik Heim</name>
<name sortKey="Hochhaus, Andreas" sort="Hochhaus, Andreas" uniqKey="Hochhaus A" first="Andreas" last="Hochhaus">Andreas Hochhaus</name>
<name sortKey="Hughes, Timothy P" sort="Hughes, Timothy P" uniqKey="Hughes T" first="Timothy P." last="Hughes">Timothy P. Hughes</name>
<name sortKey="Khoury, H Jean" sort="Khoury, H Jean" uniqKey="Khoury H" first="H. Jean" last="Khoury">H. Jean Khoury</name>
<name sortKey="Kim, Dong Wook" sort="Kim, Dong Wook" uniqKey="Kim D" first="Dong-Wook" last="Kim">Dong-Wook Kim</name>
<name sortKey="Kim, Hyeoung Joon" sort="Kim, Hyeoung Joon" uniqKey="Kim H" first="Hyeoung-Joon" last="Kim">Hyeoung-Joon Kim</name>
<name sortKey="Larson, Richard A" sort="Larson, Richard A" uniqKey="Larson R" first="Richard A." last="Larson">Richard A. Larson</name>
<name sortKey="Lipton, Jeffrey H" sort="Lipton, Jeffrey H" uniqKey="Lipton J" first="Jeffrey H." last="Lipton">Jeffrey H. Lipton</name>
<name sortKey="Roboz, Gail J" sort="Roboz, Gail J" uniqKey="Roboz G" first="Gail J." last="Roboz">Gail J. Roboz</name>
<name sortKey="Rosti, Gianantonio" sort="Rosti, Gianantonio" uniqKey="Rosti G" first="Gianantonio" last="Rosti">Gianantonio Rosti</name>
<name sortKey="Roy, Lydia" sort="Roy, Lydia" uniqKey="Roy L" first="Lydia" last="Roy">Lydia Roy</name>
<name sortKey="Sillaber, Christian" sort="Sillaber, Christian" uniqKey="Sillaber C" first="Christian" last="Sillaber">Christian Sillaber</name>
<name sortKey="Stone, Richard M" sort="Stone, Richard M" uniqKey="Stone R" first="Richard M." last="Stone">Richard M. Stone</name>
<name sortKey="Van Tornout, Jan" sort="Van Tornout, Jan" uniqKey="Van Tornout J" first="Jan" last="Van Tornout">Jan Van Tornout</name>
</noCountry>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</region>
</country>
<country name="États-Unis"><noRegion><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</noRegion>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</country>
<country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</region>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</country>
<country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</region>
</country>
<country name="Italie"><noRegion><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</noRegion>
<name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</country>
<country name="Argentine"><noRegion><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</noRegion>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</region>
</country>
<country name="Suisse"><noRegion><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</noRegion>
</country>
<country name="Brésil"><region name="État de São Paulo"><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</noRegion>
</country>
<country name="Autriche"><region name="Vienne (Autriche)"><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</region>
</country>
<country name="Australie"><noRegion><name sortKey="Apperley, Jane F" sort="Apperley, Jane F" uniqKey="Apperley J" first="Jane F." last="Apperley">Jane F. Apperley</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 008405 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 008405 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:09-0326540
   |texte=   Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.